多靶点治疗激素抵抗型肾病综合征的临床研究  

Clinical trial on the effect of multi-target therapy on steroid-resistant nephrotic syndrome

作　　者：王健英[1] 赵军[1] 王臻[1] 

机构地区：[1]山东省潍坊市人民医院肾内科,261041

出　　处：《中国实用医药》2009年第16期63-64,共2页China Practical Medicine

摘　　要：目的研究多种免疫抑制剂联合治疗激素抵抗型肾病综合征的临床疗效。方法14例患者均接受小剂量环孢素A(CsA)和来氟米特联合中等剂量的强的松治疗,在治疗后第2、4、6、8、12周动态监测各项临床指标。结果24h尿蛋白定量较治疗前明显下降,血浆白蛋白在治疗后明显升高,完全缓解率为64.3%,总有效率为86.7%。结论多靶点治疗激素抵抗型肾病综合征有显著疗效,并且不良反映少,安全性较高。Objective To investigate the clinical effect of cyclosporine （CsA） combined with lefiunomide and steroid in the treatment of steroid-resistant nephrotic syndrome. Methods The 14 patients with steroid-resistant nephrotic syndrome treated with leflunomide , CsA and prednisone. Clinical data were observed in the 2nd,4th,6th,8th, and 12th week. Results After receiving multi-target therapy , the proteinuria was decreased significantly（P 〈 0. 01 ）, Serum albumin was increased significantly （ P 〈 0. 01 ）, Complete relieving rate was 64. 3% ,and total effective rate was 86. 7%. Conclusion Multi-target therapy with CsA,leflunomide and steroid was an effective induction therapy with mild adverse effects for steroid-resistant nephrotic syndrome.

关 键 词：来氟来特 环孢素A 激素 激素抵抗型肾病综合征 

分 类 号：R692.3[医药卫生—泌尿科学]